Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.
Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Di Maio VC, et al. J Antimicrob Chemother. 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17. J Antimicrob Chemother. 2016. PMID: 26679249
Non-invasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis.
Calvaruso V, Celsa C, Cristoferi L, Scaravaglio M, Smith R, Kaur S, Di Maria G, Capodicasa L, Pennisi G, Gerussi A, Nofit E, Malinverno F, Lampertico P, Cazzagon N, Marzioni M, Vespasiani-Gentilucci U, Colapietro F, Andreone P, De Nalda AL, Rigamonti C, Viganò M, Giannini EG, Russello M, Vanni E, Cerini F, Orlandini A, Brunetto M, Niro GA, Vettori G, Castellaneta A, Cardinale V, Alvaro D, Mega A, Palitti VP, Cossiga V, Morisco F, Bellanti F, Baiocchi L, Fabris L, Persico M, Degasperi E, Labanca S, Bonaiuto E, Pezzato F, Federico A, Petta S, Di Marco V, Mells GF, Culver E, Invernizzi P, Cammà C, Carbone M. Calvaruso V, et al. Among authors: vespasiani gentilucci u. Clin Gastroenterol Hepatol. 2024 Dec 12:S1542-3565(24)01070-X. doi: 10.1016/j.cgh.2024.10.020. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39674236
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease.
Jamialahmadi O, De Vincentis A, Tavaglione F, Malvestiti F, Li-Gao R, Mancina RM, Alvarez M, Gelev K, Maurotti S, Vespasiani-Gentilucci U, Rosendaal FR, Kozlitina J, Pajukanta P, Pattou F, Valenti L, Romeo S. Jamialahmadi O, et al. Among authors: vespasiani gentilucci u. Nat Med. 2024 Dec;30(12):3614-3623. doi: 10.1038/s41591-024-03284-0. Epub 2024 Dec 9. Nat Med. 2024. PMID: 39653778 Free PMC article.
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease.
Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U, Qadri SF, Caiazzo R, Verkindt H, Saponaro C, Kerr-Conte J, Baud G, Marciniak C, Chetboun M, Oukhouya-Daoud N, Blanck S, Vandel J, Olsson L, Chakaroun R, Gnemmi V, Leteurtre E, Lefebvre P, Haas JT, Yki-Järvinen H, Francque S, Staels B, Le Roux CW, Tremaroli V, Mathurin P, Marot G, Romeo S, Pattou F. Raverdy V, et al. Among authors: vespasiani gentilucci u. Nat Med. 2024 Dec;30(12):3624-3633. doi: 10.1038/s41591-024-03283-1. Epub 2024 Dec 9. Nat Med. 2024. PMID: 39653777 Free PMC article.
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration.
Rosato V, Nevola R, Dallio M, Di Micco P, Spinetti A, Zeneli L, Ciancio A, Milella M, Colombatto P, D'Adamo G, Rosselli Del Turco E, Gallo P, Falcomatà A, De Nicola S, Pugliese N, D'Ambrosio R, Soria A, Colella E, Federico A, Brunetto M, Vespasiani-Gentilucci U, Aghemo A, Lampertico P, Izzi A, Mastrocinque D, Claar E. Rosato V, et al. Among authors: vespasiani gentilucci u. J Clin Med. 2024 Sep 28;13(19):5807. doi: 10.3390/jcm13195807. J Clin Med. 2024. PMID: 39407867 Free PMC article.
Integrating PNPLA3 into clinical risk prediction.
Chen VL, Vespasiani-Gentilucci U. Chen VL, et al. Among authors: vespasiani gentilucci u. Liver Int. 2024 Sep 16. doi: 10.1111/liv.16103. Online ahead of print. Liver Int. 2024. PMID: 39282715 Review.
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study.
Gallo P, De Vincentis A, Terracciani F, Falcomatà A, Pace Palitti V, Russello M, Vignone A, Alvaro D, Tortora R, Biolato M, Pompili M, Calvaruso V, Marzia V, Tizzani M, Caneglias A, Frigo F, Gesualdo M, Marzano A, Rosato V, Claar E, Villani R, Izzi A, Cozzolongo R, Cozzolino A, Airoldi A, Mazzarelli C, Distefano M, Iegri C, Fagiuoli S, Messina V, Ragone E, Sacco R, Cacciatore P, Masutti F, Crocé SL, Moretti A, Flagiello V, Di Pasquale G, Picardi A, Vespasiani-Gentilucci U. Gallo P, et al. Among authors: vespasiani gentilucci u. J Clin Med. 2024 Jul 6;13(13):3965. doi: 10.3390/jcm13133965. J Clin Med. 2024. PMID: 38999529 Free PMC article.
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.
De Vincentis A, Ampuero J, Terracciani F, D'Amato D, Gerussi A, Cristoferi L, Cazzagon N, Bonaiuto E, Floreani A, Calvaruso V, Cadamuro L, Degasperi E, Morgando A, Vanni E, Lleo A, Colapietro F, Alvaro D, Castellaneta A, Labanca S, Viganò M, Distefano M, Pace Palitti V, Ricci C, De Matthaeis N, Marzioni M, Gómez-Dominguez E, Montero JL, Molina E, Garcia-Buey L, Casado M, Berenguer M, Conde I, Simon MA, Fuentes J, Costa-Moreira P, Macedo G, Jorquera F, Morillas RM, Presa J, Sousa JM, Gomes D, Santos L, Olveira A, Hernandez-Guerra M, Aburruza L, Santos A, Carvalho A, Uriz J, Gutierrez ML, Perez E, Chessa L, Pellicelli A, Marignani M, Muratori L, Niro GA, Brunetto M, Ponziani FR, Pompili M, Marra F, Galli A, Mussetto A, Alagna G, Simone L, Bertino G, Rosina F, Cozzolongo R, Russello M, Baiocchi L, Saitta C, Terreni N, Zolfino T, Rigamonti C, Vigano R, Cuccorese G, Pozzoni P, Pedone C, Grasso S, Picardi A, Invernizzi P, Sacco R, Izzi A, Fernandez-Rodriguez C, Vespasiani-Gentilucci U, Carbone M; RECAPITULATE Investigators. De Vincentis A, et al. Among authors: vespasiani gentilucci u. Clin Gastroenterol Hepatol. 2024 Oct;22(10):2062-2074.e11. doi: 10.1016/j.cgh.2024.05.008. Epub 2024 May 22. Clin Gastroenterol Hepatol. 2024. PMID: 38782175
Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population.
De Vincentis A, Tavaglione F, Namba S, Kanai M, Okada Y, Kamatani Y, Maurotti S, Pedone C, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. De Vincentis A, et al. Among authors: vespasiani gentilucci u. Aliment Pharmacol Ther. 2024 Jun;59(11):1402-1412. doi: 10.1111/apt.17953. Epub 2024 Mar 18. Aliment Pharmacol Ther. 2024. PMID: 38497224
135 results